Job description

Lower urinary tract symptoms (LUBS) affect older men and their frequency and severity increase with age. The histological diagnosis of benign prostatic hyperplasia (BPH) increases from 25% in the age group between 40 and 49 years to 80% in the age group between 70 and 79 years. However, this hyperplasia can lead to bladder outlet obstruction (VOS) secondary to benign prostatic enlargement (BPE), causing storage and emptying symptoms, associated with considerable impairment in quality of life.

The surgical treatment of BPH has continually evolved in recent years. The current gold standard for endoscopic treatment of BPH is transurethral resection of the prostate (TURP). Other innovative techniques have been developed, including Urolift, transurethral laser enucleation (holmium, thulium) and Aquablation therapy. Newer technologies for the management of BPH include the Optilume BPH Cathter System (Optilume®, Urotronic Inc, Minneapolis, USA) and Rezum water vapor therapy (Rezum System, Boston Scientific, Marlborough, MA ).

The Optilume BPH Catheter System is a device/drug combination technology consisting of two catheters: the Optilume BPH Prostatic Pre-Dilation Catheter, which is a non-drug-coated catheter used to initiate commissurotomy between the lateral lobes of the prostate. prostate, and the DCB Optilume BPH Prostatic Dilation Catheter, which is a drug-coated catheter used to complete the commissurotomy and transfer the drug (paclitaxel) to the pre-dilated prostatic urethra and anterior commissure. Thus, the device applies mechanical dilation to open the prostatic urethral lumen to increase urine flow, followed by transfer of the drug paclitaxel to inhibit cell proliferation and maintain this dilation.

The objective of this study is to compare patient experience, symptom relief, and functional improvement when using the Optilume BPH Catheter System (Optilume®, Urotronic Inc, Minneapolis, USA) versus traditional therapy. by Rezum water vapor (Rezum System, Boston Scientific, Marlborough, MA) during a randomized, blinded clinical study.

Qualifications

• Hold a bachelor's degree (BSc) in health sciences 
• Have an interest in clinical research 
• Advanced command of French and English, written and oral 
• Professional and intellectual rigor 
• Works well in a team, motivated and autonomous 
• Knowledge of statistical analysis software (an asset) 
• Applicants must be Canadian citizens or permanent residents in Quebec or hold a visa allowing them to study there

What we offer

• Full-time position, 35 hours per week  
• Flexibility of schedules (teleworking/hybrid/face-to-face)  
• Scholarship: A scholarship will be offered to the student (amount to be determined but will be competitive). The student must commit to submitting a scholarship application to a recognized granting organization (e.g.: FRQS, IRSC)
• Be registered in a master’s program at the University of Montreal (fall 2024/winter 2025)

To apply for this position

Interested candidates are requested to send their full CV, accompanied by university transcripts and contact details of 2-3 references, to:
 naeem.bhojani@gmail.com

It is “essential” to attach your CV for your application to be considered.

We thank everyone who applies, but will only contact those selected for a test or interview.

The CRCHUM invites women, Indigenous people, visible minorities, ethnic minorities and people with limitations to submit their applications. The CRCHUM adopts a broad and inclusive definition of diversity that goes beyond applicable laws.

The CRCHUM therefore encourages all people, regardless of their characteristics, to apply. In accordance with Canadian immigration requirements, please note that priority will be given to Canadian citizens and permanent residents.